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What’s already known about this topic? 
 Hyperhidrosis is characterised by uncontrollable excessive sweating, which occurs at rest, 
regardless of temperature; symptoms can significantly affect quality of life.  
 Hyperhidrosis with no discernible cause is known as primary hyperhidrosis.  
 Despite the existence of a wide range of treatments for primary hyperhidrosis and a large 
number of clinical studies, there is uncertainty regarding optimal patient management and 
substantial variation in the availability of secondary care treatments in the UK. 
What does this study add? 
 This high-quality systematic review synthesises the large amount of research evidence for 
the effectiveness and safety of treatments for primary hyperhidrosis, which unfortunately is 
of limited quality and few firm conclusions can be drawn.  
 There is moderate quality evidence to support the use of botulinum toxin injections for 
axillary hyperhidrosis.  
 Recommendations for robust research are made, based on the results of the systematic 
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review, alongside clinical and patient advice. 
Summary 
Background 
Hyperhidrosis is uncontrollable excessive sweating, which occurs at rest, regardless of temperature.  
The symptoms of hyperhidrosis can significantly affect quality of life. 
Objectives 
To undertake a systematic review of the clinical effectiveness and safety of treatments available in 
secondary care for the management of primary hyperhidrosis. 
Methods 
Fifteen databases (including trial registers) were searched to July 2016 to identify studies of 
secondary care treatments for primary hyperhidrosis. For each intervention randomised controlled 
trials (RCTs) were included, where available; where RCT evidence was lacking, non-randomised trials 
or large prospective case series were included. Outcomes of interest included disease severity, 
sweat rate, quality of life, patient satisfaction and adverse events. Trial quality was assessed using a 
modified version of the Cochrane Risk of Bias tool. Results were pooled in pair-wise meta-analyses 
where appropriate, otherwise a narrative synthesis was presented. 
Results 
Fifty studies were included in the review; 32 RCTs, 17 non-randomised trials and one case series. 
Studies varied in terms of population, intervention and methods of outcome assessment. Most 
studies were small, at high risk of bias and poorly reported. The interventions assessed were 
iontophoresis, botulinum toxin injections (BTX), anticholinergic medications, curettage and newer 
energy-based technologies that damage the sweat gland. 
Conclusions 
The evidence for the effectiveness and safety of treatments for primary hyperhidrosis is limited 
overall, and few firm conclusions can be drawn. However, there is moderate quality evidence to 
support the use of BTX for axillary hyperhidrosis. A trial comparing BTX with iontophoresis for 
palmar hyperhidrosis is warranted. 
Introduction 
Hyperhidrosis is characterised by uncontrollable excessive and unpredictable sweating, which occurs 
at rest, regardless of temperature. Primary hyperhidrosis, which is the focus of this review, has no 
discernible cause. It most commonly involves the axillae, palms, and soles, but may also involve the 
face, groin or any area of the body.  
 
Primary hyperhidrosis is thought to affect at least 1% of the UK population.1 The symptoms of 
hyperhidrosis can significantly affect quality of life, and can lead to social embarrassment, loneliness, 
anxiety and depression. It can impair work activities or studying in those handling pens, paper and 
electronic equipment. Functional problems may arise from skin maceration and soreness. Severely 
affected patients also may have secondary microbial infections. The unpredictable and 
uncontrollable nature of the condition can make it very distressing for sufferers. 
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In primary care, patients may initially be advised to make lifestyle changes such as restricting 
stimulant-containing foods, losing weight and avoiding clothing that can make sweating worse. First 
line treatment includes topical pharmacological agents: aluminium chloride has been shown to be 
effective for mild-to-moderate axillary hyperhidrosis and formaldehyde solution can be prescribed 
for plantar hyperhidrosis.2,3 Unfortunately, skin irritation is very common with these antiperspirants 
and often forces discontinuation of the treatment.4 Patients may be referred to a dermatologist if 
treatment fails or is not tolerated. However, current recommendations are not underpinned by 
robust evidence and there is significant variation in the availability of treatments for primary 
hyperhidrosis in secondary care in the UK. Further clinical trials may be required, in particular 
comparing the effectiveness of treatments prescribed by a dermatologist, but first a thorough 
review of the available evidence is warranted. 
 
Objectives 
To undertake a systematic review of the clinical effectiveness and safety of treatments available in 
secondary care for the management of patients with refractory primary hyperhidrosis. 
 
Methods 
A protocol for the systematic review was developed and registered on PROSPERO (number 
CRD42015027803). The review included studies of patients (adults and children) with primary 
hyperhidrosis. Studies of any treatment for hyperhidrosis offered in secondary care for prescription 
by dermatologists and minor surgical treatments were eligible for inclusion. Endoscopic thoracic 
sympathectomy was not included as it is not recommended by many practitioners: it is generally 
considered only as an intervention of last resort due to its significant risks and common adverse 
effects such as compensatory hyperhidrosis.5  
For each intervention randomised controlled trials (RCTs) were included, where available. For 
interventions where RCT evidence was lacking, non-randomised controlled trials (non-RCTs) or large 
prospective case series were included. Recently published high quality systematic reviews were also 
considered if they were directly relevant. Outcomes of interest included disease severity, sweat rate, 
quality of life, patient satisfaction and adverse events. 
Potentially relevant studies were identified through literature searching. Twelve databases were 
searched in January 2016 (including MEDLINE, EMBASE and the Cochrane Central Register of 
Controlled Trials). No date or language limits were applied. The MEDLINE search strategy (which 
identified the greatest number of records) is presented in Supplementary Appendix 1. Clinical 
advisors were consulted for additional studies and reference lists of relevant systematic reviews 
were manually searched. Information on studies in progress and unpublished research was sought 
by searching conference proceedings and trial registers, in July 2016. 
Two researchers (RW and J J-D) undertook the screening of titles and abstracts obtained through the 
search, although the library was split between the researchers, rather than each record being double 
screened. A sample of just over 10% of records was double screened in order to assess the level of 
agreement between the researchers; it was planned to undertake full double screening if the level of 
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agreement was poor, but this was not necessary as the level of agreement between researchers was 
96.2%. Full manuscripts of potentially relevant studies were obtained and independently screened 
by two researchers (RW and J J-D), using pre-defined eligibility criteria. Disagreements were resolved 
through discussion or consultation with a third researcher. Relevant foreign language studies were 
translated and included. 
Data were extracted directly into a standardised, piloted, spreadsheet developed in Microsoft Excel 
(RW, AL and J J-D). Data extracted included study design, sample size, participant characteristics 
(body site treated, age, sex, previous treatments, baseline disease severity), treatment 
characteristics (dose, frequency, duration), outcomes assessed (measurement tool and time point) 
and results. Data extraction was conducted by one researcher and checked for accuracy by a second. 
In cases of multiple publications of the same study, the publication with the largest sample or 
longest follow-up was treated as the main source. Where possible we extracted intention-to-treat 
(ITT) data. Where results data were missing or limited (e.g. only presented in graphical format, or 
conference abstracts), authors were contacted and, where relevant, manufacturer trials registers 
were consulted for further data. If the authors did not respond, data from graphs were extracted 
using Graph Grabber (Quintessa) software.  
The quality of RCTs and non-RCTs was assessed using a modified version of the Cochrane Risk of Bias 
tool by one researcher and checked for accuracy by a second (RW, AL and J J-D).6 An additional 
question relating to the similarity of treatment groups at baseline was added.7 In addition, a 
question about ‘within patient’ study designs was added, owing to concerns about the validity of 
certain outcome measures in ‘within patient’ study designs, in which patients receive different 
interventions on different sides of the body (i.e. the left versus the right axilla). See Supplementary 
Appendix 2 for the results of the risk of bias assessment. Case series were not formally quality-
assessed; their results were presented as supporting evidence. No systematic reviews were included 
in the review except as a source of relevant studies, so they were not quality assessed. 
Results were pooled in pair-wise meta-analyses if at least two studies of the same intervention and 
comparator reported the same outcome and were considered sufficiently similar for analysis to be 
appropriate and feasible. Otherwise, results were summarised in a narrative synthesis. Where meta-
analyses were performed, dichotomous outcomes were combined to estimate pooled risk ratios (RR) 
and continuous outcomes were combined to estimate pooled mean differences (MD) using random-
effects DerSimonian-Laird meta-analyses.8 Statistical heterogeneity was assessed using the I2 
statistic and visual inspection of forest plots. Studies using different units of analysis (i.e. axilla in 
half-side comparisons versus patients in between-patient comparisons) were pooled where deemed 
appropriate and reported in separate subgroups. For studies that included two separate intervention 
groups with two different doses and used one control group, data from each intervention group 
were entered separately to explore any dose response effect, and the number of participants in the 
control group was divided by two to reduce the risk of double counting data.9 Although this 
approach may artificially reduce the power of the study in the meta-analysis and does not account 
for potential correlation between the two active treatment groups, a separate analysis combining 
the two arms showed no significant difference in results.  
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Meta-regressions and other subgroup analyses were considered inappropriate due to the small 
number of studies. All analyses were conducted using Review Manager 5.3. 
Clinical and patient advisors contributed to the interpretation of the results. 
 
Results  
The electronic searches identified a total of 4057 records; the flow diagram of the study selection 
process is presented in Figure 1.  
Supplementary Appendix 3 presents the 155 records that met the inclusion criteria for the 
systematic review. For each intervention for which there were RCTs or non-randomised comparative 
studies available, less robust studies were excluded, resulting in 93 small case series being excluded 
from the review. Five additional studies were excluded because they were systematic reviews that 
were not considered to be sufficiently good quality, up to date or directly relevant to be relied upon, 
resulting in 57 records (reporting 48 studies) identified for inclusion in the review. 
An additional two studies were identified from the separate searches of conference proceedings and 
trial registers (flow diagram presented in Supplementary Appendix 4). Therefore, a total of 50 
studies were included in the review: 32 RCTs, 17 non-RCTs and one case series. 
Study characteristics 
Studies varied in terms of country of origin (indicating climate and population differences), 
intervention and the methods of outcome assessment. Most studies were small (sample sizes 
ranged from 4 to 339, with most studies including fewer than 50 patients), at high risk of bias and 
poorly reported, see Supplementary Appendix 2 for further details. The interventions assessed were 
iontophoresis, botulinum toxin (BTX), anticholinergic medications, curettage and newer technologies 
that damage the sweat gland. The majority of studies only included adult patients and the majority 
of participants across the studies were female. Where reported, baseline disease severity was 
moderate to severe, with a Hyperhidrosis Disease Severity Scale (HDSS) score of 3-4 and/or a sweat 
rate of at least 50 mg/5 minutes. The site of hyperhidrosis differed between studies of different 
interventions. A summary of the study characteristics is presented in Table 1, with further details 
presented in Supplementary Appendix 5. 
Clinical effectiveness 
This section presents a summary of the results, presented by intervention. Further results of each 
study are presented in Supplementary Appendix 5. 
Iontophoresis 
Ten studies (4 RCTs, 5 non-RCTs, 1 case series) of iontophoresis were included.10-19 All were at a high 
or unclear risk of bias. There were a number of differences in the iontophoresis interventions used 
across these studies with variations in the medium used (tap water, with aluminium chloride or an 
anticholinergic added, or a “dry type” device), the electric current used, and the frequency of 
iontophoresis sessions. No meta-analysis was possible owing to the differences between 
interventions and outcomes assessed.  
Three very small studies (2 RCTs and 1 interrupted time series) with short follow-up times compared 
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tap water iontophoresis with placebo for palmar hyperhidrosis10-12 and found a positive effect of 
iontophoresis as assessed by gravimetry or iodine starch test. This finding was supported by a larger 
case series.13 
Of two small non-randomised comparisons of a hand-held “dry type” iontophoresis device 
compared with no treatment;14,15 only one found a statistically significant reduction in sweating, 
assessed by gravimetry.14  
Two studies compared iontophoresis alone with iontophoresis combined with anticholinergic 
therapy for palmoplantar hyperhidrosis; one RCT found no significant benefit with the addition of 
oral oxybutynin,16 while a non-RCT reported that iontophoresis with topical glycopyrrolate resulted 
in a longer duration of effect.17 The addition of anticholinergic therapy was associated with dry 
throat, mouth or eyes in some patients. 
Two studies (1 RCT, 1 non-RCT)18,19 compared iontophoresis with BTX injections for palmar 
hyperhidrosis. The RCT found a statistically and clinically significant difference in treatment response 
(HDSS) and patient reported symptoms between the two interventions favouring BTX at four weeks 
from baseline.18 This result was supported by the non-RCT, but the difference in treatment benefit 
was no longer statistically significant at six or 12 months.19 Patients receiving BTX were more likely to 
report mild to moderate pain associated with treatment. 
Overall, there is very low quality but consistent evidence suggesting a short term beneficial effect of 
tap water iontophoresis in the treatment of palmar hyperhidrosis. There is inconsistent evidence 
regarding the beneficial effect of adding anticholinergic therapy to iontophoresis for palmoplantar 
hyperhidrosis. There is very low quality evidence suggesting that BTX is more effective than 
iontophoresis for palmar hyperhidrosis in the short term. No serious adverse events related to 
iontophoresis were reported. 
Botulinum toxin (subcutaneous injection) 
Twenty-three studies of BTX, delivered by subcutaneous injection, were included. There was some 
variation in the BTX used in these trials. Most studies used BTX type A, only two used type B. Where 
stated, the most common dosage of  BTX-A was 50 U, although some studies used up to 250 U.  The 
studies of BTX-B used 2500 U or 5000 U.  
For axillary hyperhidrosis, BTX was compared with placebo in nine studies (8 RCTs,20-27 1 open label 
continuation study28), no treatment in three studies (non-RCTs29-31), and with curettage in four 
studies (1 RCT,32 3 non-RCTs33-35).  
For the comparison with placebo, meta-analysis of some trials was possible for the following 
outcomes: patient-reported symptom improvement (HDSS reduction of at least 2 points RR: 3.30, 
95% CI: 2.46 to 8.32; p<0.001, I2=0%, 2 studies) (Fig. 2), sweat reduction (gravimetry) expressed as 
mean differences (MD at 16 weeks: -66.93, 95% CI: -82.76 to -51.10; p<0.001, I2=0%, 3 studies) (Figs 
3-4) or risk ratios (RR at 16 weeks: 2.87, 95% CI: 1.94 to 4.26; p<0.001, I2=48%, 3 studies) (Figs 5-7), 
and quality of life (MD: -4.80, 95% CI: -5.67 to -3.94; p<0.001, I2=3%, 2 studies) (Fig. 8). Overall, the 
meta-analyses showed a large and clinically significant effect of BTX for axillary hyperhidrosis; 
benefits were largely sustained at 16 weeks follow-up (Figs 4 and 6). The placebo controlled BTX 
trials that were not included in the meta-analyses also reported clinically relevant improvements in 
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sweating26,27 and improvements in quality of life.21,28,36  No serious or severe treatment related 
adverse events were reported; the most common treatment-related adverse events were injection-
site pain and compensatory sweating.  
The three non-RCTs comparing BTX with no treatment reported broadly similar results; significant 
reductions in sweating but injection-site pain associated with BTX injections.29-31 
Results of the studies comparing BTX with curettage are described in the ‘Curettage’ section below. 
For palmar hyperhidrosis, BTX was compared with placebo in three RCTs, which reported a small 
statistically significant reduction in sweating at three to thirteen weeks, measured by gravimetry37 or 
sweat area,38 but not by iodine starch test.36 Patients’ assessment of disease severity was statistically 
significantly improved in the BTX group in all three RCTs. One of the RCTs reported a high incidence 
of treatment related adverse events, including decreased grip strength, muscle weakness and dry 
mouth.36 Two non-randomised studies compared BTX with no treatment.30,39 Results were similar to 
the findings of the RCTs. 
Overall, there is moderate quality evidence of a large statistically significant effect of BTX injections 
on symptoms of axillary hyperhidrosis in the short and medium term (up to 16 weeks) compared 
with placebo. Short term evidence indicated that BTX may improve quality of life compared with 
placebo.  BTX is associated with mild adverse events, notably injection-site pain. Evidence comparing 
the effectiveness of BTX injections to the axillae with curettage is very low quality and uncertain. 
There is very low quality evidence suggesting that BTX injections had a small positive effect on 
palmar hyperhidrosis symptoms compared with placebo or no treatment, although adverse events 
were reported. As stated above, there is very low quality evidence suggesting that BTX is more 
effective than iontophoresis for palmar hyperhidrosis in the short term. There is insufficient 
evidence on the effect of BTX injections on quality of life in palmar hyperhidrosis. 
Topical botulinum toxin 
Only one very small placebo-controlled RCT (unclear risk of bias) evaluated the efficacy of topically 
applied BTX for axillary hyperhidrosis; there was a greater reduction in sweating with BTX than 
placebo.40 Therefore there is insufficient evidence to conclude on the effectiveness and safety of 
topical BTX for primary hyperhidrosis. 
Anticholinergics 
Studies of three anticholinergics were identified: topical glycopyrrolate; oral oxybutynin and oral 
methantheline bromide. No meta-analysis was possible owing to the differences between 
interventions and outcomes assessed. Two small low-quality (high or unclear risk of bias) RCTs 
evaluated short term treatment with glycopyrrolate wipes against placebo, used for hyperhidrosis of 
the axilla41 or the face.42 Both studies found a significant treatment benefit in terms of sweating 
(gravimetry), but improvement in HDSS was seen only in patients receiving treatment for axillary 
hyperhidrosis.41 There was limited and inconclusive evidence from one non-RCT43 regarding the 
effectiveness (HDSS) and safety of glycopyrrolate spray compared with BTX injections for axillary 
hyperhidrosis. There were no studies assessing the clinical effectiveness of oral glycopyrrolate. 
Three placebo-controlled RCTs evaluated the effectiveness and safety of oral oxybutynin for 
hyperhidrosis of the axilla and palm,44 foot45 and generalised hyperhidrosis,46 and two placebo-
controlled RCTs assessed oral methantheline bromide for axillary and palmar hyperhidrosis.47,48 All 
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studies were at a high or unclear risk of bias and reported treatment benefits as well as a 
significantly higher incidence of dry mouth symptoms in patients receiving active therapy. 
Overall, the evidence for anticholinergic medications was limited, but suggested short term benefits 
of topical glycopyrrolate, oral oxybutynin and oral methantheline bromide on hyperhidrosis 
symptoms. Oral oxybutynin and methantheline bromide were also associated with dry mouth 
adverse events. 
Curettage 
Nine studies (4 RCTs, 5 non-RCTs) evaluated curettage for axillary hyperhidrosis. All were at high risk 
of bias. No meta-analysis was possible owing to the differences between interventions and 
outcomes assessed. 
Of four studies (1 RCT, 3 non-RCTs) that compared curettage with BTX in axillary hyperhidrosis,32-35 
only the small RCT32 found a statistically significant difference in HDSS score (at three and six months 
follow-up) favouring BTX. The other studies found no significant difference between treatment 
groups in sweating, quality of life and satisfaction outcomes. However, where reported, the 
incidence of adverse events was higher with curettage than BTX. 
Five studies (3 RCTs, 2 non-RCTs) compared suction curettage with other surgical interventions: 
radical skin excision; liposuction curettage, radical skin excision and a skin-sparing technique (Shelley 
radical skin excision); curettage with and without aggressive manual shaving; tumescent suction 
curettage and laser.49-53 Overall, there is very low quality evidence regarding the relative 
effectiveness and safety of curettage compared with other minor surgical interventions for axillary 
hyperhidrosis. Compared with the more radical excision techniques, there is insufficient evidence to 
demonstrate a clinically significant difference in sweat reduction, patient satisfaction or safety. 
Energy-based ‘destructive’ technologies 
Three RCTs evaluated the efficacy and safety of laser epilation for axillary hyperhidrosis.53-55 All were 
at high risk of bias and, as well as other study differences, the wavelength used varied between the 
studies. No meta-analysis was possible owing to the differences between interventions and 
outcomes assessed. One RCT compared laser with curettage (described in the ‘Curettage’ section 
above).53 Two small RCTs compared laser epilation with no treatment; one found that sweating was 
visibly reduced on the laser-treated side compared with the untreated side at one month,55 but the 
other study found no significant difference between treated and untreated sides in sweat reduction 
at 12 months.54 Both studies reported no serious adverse events. 
One non-randomised study (high risk of bias) compared the efficacy of fractionated microneedle 
radiofrequency with a sham control for axillary hyperhidrosis.56 The study reported significantly 
better results in mean HDSS scores and sweating intensity at 21 weeks follow-up, with transient but 
not severe adverse events. 
One RCT (high risk of bias) compared a microwave device with sham treatment for axillary 
hyperhidrosis.57 The study found that microwave therapy was more effective than placebo at 
reducing patient reported disease severity, although there was no evidence of a significant 
difference in the proportion of patients achieving 50% sweat reduction at up to six months. Adverse 
events were generally transient and none were considered severe.  
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Two small RCTs (high risk of bias) compared micro-focused ultrasound with sham treatment for 
axillary hyperhidrosis, reported in a single publication.58 The studies reported some benefit in terms 
of sweating and HDSS.  
Overall, there is insufficient evidence regarding the safety and effectiveness of laser epilation, 
fractionated microneedle radiofrequency, microwave therapy or ultrasound therapy for axillary 
hyperhidrosis. 
Discussion 
The evidence for the effectiveness and safety of second line treatments for primary hyperhidrosis is 
limited overall. Most of the included studies were small, at high risk of bias and poorly reported; only 
one RCT was judged to have a low overall risk of bias. There was insufficient evidence to draw firm 
conclusions regarding the relative effectiveness and safety of most of the available treatments for 
primary hyperhidrosis in secondary care. 
There is, however, moderate quality evidence of a large effect of BTX injections on symptoms of 
axillary hyperhidrosis in the short to medium term, although injections were associated with 
transient injection-site pain. Evidence for other interventions is of low or very low quality. Although 
the evidence for iontophoresis is very low quality, it is consistent, suggesting that there is a short 
term beneficial effect of tap water iontophoresis in the treatment of palmar hyperhidrosis; no 
serious adverse events were reported. There is very low-quality evidence suggesting short term 
benefits of topical glycopyrrolate, oral oxybutynin and oral methantheline bromide on hyperhidrosis 
symptoms. However, oral oxybutynin and methantheline bromide were associated with dry mouth 
adverse events. There were no studies assessing the clinical effectiveness of oral glycopyrrolate or 
propantheline bromide for hyperhidrosis despite being commonly used anticholinergic drugs in 
hyperhidrosis. There was insufficient evidence to demonstrate a clinically significant difference 
between curettage and other minor surgical interventions or BTX for axillary hyperhidrosis. Evidence 
was very limited regarding the newer energy based ‘destructive’ technologies. 
Despite its large volume the poor quality of much of the available research evidence is a limitation of 
this review. The only comparison for which adequate data were available to undertake meta-analysis 
was that between BTX and placebo for axillary hyperhidrosis. It was not feasible to undertake 
network meta-analysis; therefore, the comparative clinical effectiveness of the available treatments 
could not be estimated. In addition, the substantial variation among the included studies limits the 
generalisability and reliability of the results. 
Recommendations for further research 
There is limited but promising evidence for the effectiveness of BTX for palmar hyperhidrosis and 
therefore, a well conducted, adequately powered, randomised controlled trial of BTX (with 
anaesthesia), compared with iontophoresis (as the current standard treatment for palmar 
hyperhidrosis in many dermatology units), for palmar hyperhidrosis may be warranted. This trial 
should evaluate patient relevant outcomes based on a validated scale such as the new HidroQoL© 
tool. The cost of BTX plus anaesthesia is considerably higher than iontophoresis; therefore, the 
relative cost-effectiveness of these treatments should also be assessed. 
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Conclusions 
The evidence for the effectiveness and safety of treatments for primary hyperhidrosis is limited 
overall, and few firm conclusions can be drawn. However, there is moderate quality evidence to 
support the use of BTX injections for axillary hyperhidrosis. A trial comparing BTX injections with 
iontophoresis for palmar hyperhidrosis is warranted. 
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on) 
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rk 
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44 
27
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Palm Iontophore
sis (tap 
water) 
(n=11) 
Sham 
(n=11) 
N/A Unclear 
Karakoc, 
200411 
Interrupt
ed time 
series 
Turkey 15 15-
26 
47
% 
Palm Iontophore
sis (tap 
water) 
(n=15) 
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Stolman, 
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45
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201315 RCT 
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comparis
on) 
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treatment 
(right 
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Na 200714 Non-
RCT 
(half 
side 
comparis
on) 
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Korea 
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70
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Palm Iontophore
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type) 
(n=10) 
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treatment 
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Iontophore
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Naumann, 
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n of 
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m and 
UK 
U, 2 
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spaced by 
at least 16 
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U, 3 
treatments, 
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(n=30) 
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200223 
RCT USA 18 16-
50 
61
% 
Axilla BTX-A (50 
U) (n=12) 
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(n=6) 
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201322,61 
RCT Japan 152 NR 24
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Axilla BTX-A (50 
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comparis
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a 
13 21-
55 
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Axilla BTX-A 
(200 U) 
(n=13) 
Placebo 
(n=13) 
N/A Unclear 
Heckmann  
199929 
Non-
RCT 
(half 
side 
comparis
on) 
Germa
ny 
12 21-
42 
42
% 
Axilla BTX-A 
(250 U 
Dysport) 
(n=12) 
No 
treatment 
(n=12) 
followed 
by BTX-A 
(250U) 14 
days later 
N/A High 
Naver, 
200030 
Non-
RCT 
(half 
side 
comparis
on) 
Swede
n 
28 19-
57 
38
% 
Axilla 
and/or 
palm 
BTX-A 
(Botox, 
mean 104U 
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56U (palm) 
once or 
twice), 
local 
anaesthesia 
(palmar 
HH only) 
(n=28; 
palmar 
n=19; 
axillary 
n=13) 
No 
treatment 
(n=28) 
N/A High 
Wakugaw
a 200131 
Non-
RCT  
(half 
side 
comparis
on) 
Japan 20 NR NR Axilla BTX-A (50 
U Dysport) 
one side 
only (n=7) 
BTX-A (50 
U Dysport) 
both sides 
(n=13) 
No 
treatment 
(n=7) 
N/A High 
Ibrahim, 
201332 and 
Ibrahim, 
201362 
RCT     
(half 
side 
comparis
on) 
USA 20 19-
50 
65
% 
Axilla Tumescent 
suction 
curettage 
(tumescent 
anaesthesia
) (n=20)  
BTX-A 
(50 U) 
(n=20) 
N/A High 
Ottomann, 
200733 
Non-
RCT 
Germa
ny 
88 17-
39  
16
% 
Axilla Suction 
curettage 
BTX-A 
(50 U) 
N/A High 
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Risk of 
bias 
(n=41) (n=47) 
Rompel, 
200134 
Non-
RCT 
Germa
ny 
113 NR 36
% 
Axilla Suction 
curettage 
(subcutane
ous) (n=90) 
BTX-A 
(40-50 U 
Botox or 
200-250 U 
Dysport 
per axilla) 
(n=23) 
N/A High 
Vakili, 
201635 
Non-
RCT 
UK 98 16-
56 
26
% 
Axilla Micro 
Retro-
dermal 
Axillary 
Curettage 
(mRAC) 
(n=23) 
BTX-A 
(Botox) 
(n=75) 
N/A High 
Baumann, 
200536 
RCT USA 20 20-
60  
50
% 
Palm BTX-B 
(5000 U) 
(n=15) 
Placebo 
(n=5) 
N/A High 
Lowe, 
200237 
RCT      
(half 
side 
comparis
on) 
USA 19 NR  53
% 
Palm BTX-A 
(100 U) 
(n=19) 
Placebo 
(n=19)  
N/A Unclear 
Schnider, 
199738 
RCT      
(half 
side 
comparis
on) 
Austri
a 
11 23-
54  
64
% 
Palm BTX-A 
(120 U 
Dysport) 
(n=11) 
Placebo 
(n=11) 
N/A Unclear 
Yamashita
, 200839 
Non-
RCT 
(half 
side 
comparis
on) 
Japan 27 NR  22
% 
Palm BTX-A (60 
U Botox) 
(n=27) 
No 
treatment 
(n=27) 
N/A High 
 
Glogau, 
200740 
RCT     
(half 
side 
comparis
on) 
USA 12 NR 50
% 
Axilla Topical 
BTX-A 
(200 U 
Botox) 
(n=12) 
Placebo 
(n=12) 
N/A Unclear 
Mehrotra, 
201541 
 
RCT USA 38 
 
17-
68 
42
% 
Axilla Glycopyrro
late wipes 
(4% once 
daily for 4 
weeks) 
(n=12) 
Glycopyrro
late wipes 
(2% once 
daily for 4 
weeks) 
(n=12) 
Placebo 
(n=14) 
N/A High 
Hyun, 
201542 
RCT     
(half 
side 
comparis
on) 
South 
Korea 
39 20-
66 
77
% 
Face Glycopyrro
late wipes 
(2% 9 
times over 
10 days) 
(n=39) 
Placebo 
(n=39) 
N/A Unclear 
/High  
Baker, 
201343 
Non-
RCT 
UK 40 20-
41  
20
% 
Axilla Glycopyrro
late (1% 
spray) 
BTX-A 
(dose NR) 
(n=10) 
No 
treatment 
(n=10) 
High 
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ran
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le 
% 
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Interventi
on 1 
Interventi
on 2 
Interventi
on 3 
Risk of 
bias 
(n=10)   
Glycopyrro
late (2% 
spray) 
(n=10) 
Wolosker, 
201244 
RCT Brazil 50 18-
50 
 
27
% 
Primaril
y axilla 
and 
palm 
Oxybutyni
n (2.5 mg 
to 10 mg 
daily) 
(n=25) 
Placebo 
(n=25) 
N/A Unclear 
Costa, 
201445 and 
Costa, 
201563 
RCT Brazil 32 NR  0% Primaril
y feet 
Oxybutyni
n (2.5 mg 
to 10 mg 
daily) 
(n=16) 
Placebo 
(n=16) 
N/A Unclear 
Schollham
mer, 
201546 
RCT France 62 18-
62 
43
% 
Generali
sed 
(83%), 
localise
d (17%) 
Oxybutyni
n (2.5 mg 
to 7.5 mg 
daily) 
(n=32) 
Placebo 
(n=30) 
N/A Unclear 
Muller, 
201348 
 
RCT Germa
ny 
339 NR NR Axilla 
and/or 
palm 
Methanthel
ine 
bromide 
(150 mg 
daily) 
(n=171) 
Placebo 
(n=168) 
N/A Unclear/
High 
Hund, 
200447 
RCT Germa
ny 
42 18-
54 
25
% 
Axilla 
and/or 
palm 
Methanthel
ine 
bromide 
(100 mg 
daily) 
(n=23) 
Placebo 
(n=19) 
N/A High 
Bechara, 
2008a49 
RCT Germa
ny 
40 19-
57 
45
% 
Axilla Curettage 
(liposuctio
n) (n=15) 
Shelley 
(skin-
sparing 
technique) 
(n=11) 
Radical 
skin 
excision 
(modified 
Bretteville-
Jensen 
technique 
with Y-
plasty 
closure) 
(n=14) 
High 
Jemec, 
197552 
Non-
RCT 
Denma
rk 
41 NR NR Axilla Curettage 
(liposuctio
n) (n=20) 
Radical 
excision 
(n=21) 
N/A High 
Bechara, 
2008b51 
Non-
RCT 
(half 
side 
comparis
on) 
Germa
ny 
4 NR NR Axilla Curettage 
(liposuctio
n) (n=4) 
Curettage 
(liposuctio
n) + 
aggressive 
manual 
shaving 
(n=4) 
N/A High 
Tronstad, 
201450 
RCT      
(half 
side 
comparis
on) 
Norwa
y 
22 20-
44 
18
% 
Axilla Curettage 
(n=22) 
Tumescent 
suction 
curettage 
(n=22) 
N/A Unclear 
(gravimet
ry) 
High 
(DLQI) 
Leclère, 
201553 
RCT France
, 
100 NR NR Axilla Laser alone 
(924/975 
Laser 
(924/975 
Laser alone 
(975 nm) 
High 
A
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d 
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ran
ge 
Ma
le 
% 
Body 
site 
Interventi
on 1 
Interventi
on 2 
Interventi
on 3 
Risk of 
bias 
Germa
ny and 
Spain 
nm 
simultaneo
us) once 
(n=25) 
nm) 
+curettage 
once 
(n=25) 
once 
(n=25)   
Interventi
on 4: 
Suction 
curettage 
alone once 
(n=25) 
Bechara 
201254 
RCT      
(half 
side 
comparis
on) 
Germa
ny 
21 24-
66  
24
% 
Axilla Long-
pulsed 
laser (800-
nm) 5 
treatments 
at 4-week 
intervals 
(n=21) 
No 
treatment 
(n=21) 
N/A High 
Letada 
201255  
RCT     
(half 
side 
comparis
on) 
USA 6 NR  17
% 
Axilla Long-
pulsed 
laser (1064 
nm) 6 
treatments 
at monthly 
intervals 
(n=6) 
No 
treatment 
(n=6) 
N/A High 
Fatemi 
Naeini, 
201556 and 
Abtahi-
Naeini, 
201564 
Non-
RCT 
(half 
side 
comparis
on) 
Iran 25 NR  
32
% 
Axilla Fractionate
d 
microneedl
e 
radiofreque
ncy (1 
MHz of 
radiofreque
ncy 
current) 3 
sessions at 
3 week 
intervals 
(n=25) 
Sham 
fractionate
d 
microneed
le 
radiofrequ
ency 
(n=25) 
N/A High 
Glaser, 
201257 and 
Kilmer, 
201165 
RCT  USA 120 NR 43
% 
Axilla Microwave
, 2 sessions 
(approxima
tely) 
(n=81) 
Sham 
microwav
e (n=39)  
N/A High 
Nestor, 
201458 and 
Nestor 
201266 
(study 1) 
RCT      
(half 
side 
comparis
on) 
USA 14 NR  21
% 
Axilla Micro-
focused 
ultrasound 
(n=14) 
Placebo 
(n=14) 
 High 
Nestor, 
201458 and 
Nestor 
201266 
(study 2) 
RCT USA 20 21-
52  
65
% 
Axilla Micro-
focused 
ultrasound 
(n=12) 
Placebo 
(n=8) 
 High 
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